Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Genmab A/S (GNMSF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Genmab A/S $529, price $355, upside +49.0%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
GA
Broad data
Oct 3, 2026
Broad data
Oct 3, 2026
Genmab A/S
GNMSF · USUndervaluedThe stock appears undervalued with acceptable quality.
✓Fair value $528.76 · Undervalued (+49.0%)
✓Quality 72/100
!Weak Growth (revenue 5y −17.6 %/yr)
✓Highly profitable · 21.1% net margin (TTM)
✓Moderate debt · generates free cash flow
✓Wide moat 71/100
Watch Genmab A/S for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $178.74 – $499.37 · fair‑value band $247.76 – $779.69 · the $355.00 price screens below the $528.76 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Show more
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Stock analysis
Genmab A/S (GNMSF) currently trades at $355.00, while our model-based Fair Value estimate is $528.76, implying the stock looks roughly 32.9% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $599.76 per share, and 13 of the 24 models we run sit above the $355.00 price.
Bear case: the Asset-Based group reads lowest at $63.53, and 11 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $247.76 (bear) to $779.69 (bull), the price of $355.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Genmab A/S reported revenue of $3.9B in FY2025 versus $8.5B in FY2021, a compound −17.9%/yr. Reported net income was $997M in FY2025, compounding −23.8%/yr from FY2021.
Key figures
Market cap $22.3B · P/E ratio 27.0 · P/S ratio 6.99 · EPS (TTM) $13.15 · Dividend yield 1.8% · Net margin 25.9% · Return on equity 15.0% · Return on assets (EBIT) 14.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 49%, GNMSF screens cheaper than that median.
Fair Value models
Bear $247.76
Fair Value $528.76
Bull $779.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($9.94 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$286.42
$481.45
$1,103
74
EPV
$108.39
$135.40
$159.03
74
Growth DCF
$266.21
$541.32
$1,097
73
All 24 models by family
DCF Models
FCF DCF
$286.42
$481.45
$1,103
74
Owner Earnings
$222.65
$575.11
$1,315
69
5Y Revenue Exit
$146.03
$271.58
$532.64
68
5Y EBITDA Exit
$215.76
$412.57
$798.14
71
5Y P/E Exit
$241.79
$593.64
$1,071
67
10Y Revenue Exit
$184.39
$421.58
$557.56
66
10Y EBITDA Exit
$241.25
$571.73
$1,138
64
10Y P/E Exit
$260.25
$627.79
$1,227
60
Earnings-Based
Graham-Dodd
$110.42
$770.06
$1,081
63
Lynch FV
$334.53
$477.89
$621.26
61
PEG = 1.0
$334.53
$477.89
$621.26
57
EPV
$108.39
$135.40
$159.03
74
Multiples
P/E Multiple
$267.93
$357.24
$446.55
63
P/S Multiple
$164.66
$219.55
$274.43
58
P/B Multiple
$207.04
$276.05
$345.06
55
EV/EBIT
$215.09
$304.67
$394.26
65
EV/EBITDA
$179.81
$257.63
$335.45
67
EV/Revenue
$78.08
$134.53
$190.99
52
Asset-Based
NCAV (Graham)
$47.41
$63.53
$94.82
54
Growth DCF
Growth DCF
$266.21
$541.32
$1,097
73
Rev-Margin DCF
$156.23
$318.73
$640.78
68
Economic Profit
Residual Income
$107.40
$142.10
$238.57
68
ROIC Compounder
$126.16
$195.16
$261.77
71
Growth Earnings
Growth-Adj P/E
$419.84
$599.76
$779.69
67
Notify me when GNMSF reaches fair value
Put GNMSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
72/100
Of which business quality 68 · Market factors (momentum, volatility) 72
Profitability
56
Margins and returns on capital today
Quality Growth
3
Are margins and returns improving?
Cashflow
87
Earnings quality: real cash, not paper profit
Fin. Strength
68
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
71
Calm price path (market factor)
Momentum
70
Price trend over the last 3–12 months (market factor)
52W Momentum
75
Distance to the 52-week high (market factor)
Net Issuance
100
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−82.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.6%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−16.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−18.7%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−18.7% vs 2.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.62% → 34%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.2% a year for the price.
Watch GNMSF, get fair value alerts →
Recent news
News mood ⓘNews mood, the average tone of recent news (82 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Notice to Convene an Extraordinary General Meeting of Genmab A/S
Compare Genmab A/S with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Genmab A/S (GNMSF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $528.76 versus a price of $355.00, about +49% upside (undervalued).
What is the fair value of GNMSF?
Our model-based fair value for Genmab A/S is $528.76 (as of Oct 3, 2026), built from audited fundamentals. The current price: $355.00.
What is the quality score of GNMSF?
Genmab A/S has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genmab A/S (GNMSF)?
Our model-based price target is the fair value of $528.76 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario $247.76, optimistic scenario $779.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Genmab A/S stock forecast for 2026?
Our models put fair value at $528.76, about +49% upside versus a price of $355.00 (undervalued). Cautious scenario $247.76, optimistic scenario $779.69. The calculation is refreshed regularly with new filings.
What is the revenue of Genmab A/S (GNMSF)?
Genmab A/S reported trailing-twelve-month revenue of about $3.9B (latest available figure, as of Oct 3, 2026).
Does Genmab A/S pay a dividend?
Genmab A/S currently shows a dividend yield of about 1.83% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Genmab A/S (GNMSF)?
For today's price to be fair in a discounted-cash-flow model, Genmab A/S would have to grow free cash flow by +7.7 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -17.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of GNMSF use?
Our models discount Genmab A/S at 8.5 %: a base by market capitalisation (large), damped by beta 0.68, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genmab A/S that is +7.7 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Genmab A/S (GNMSF) delivered so far?
Over the past 5 years revenue at Genmab A/S grew -17.6 % a year. The price currently implies +7.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genmab A/S (GNMSF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Genmab A/S (+7.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genmab A/S (GNMSF)?
The free-cash-flow yield on the price is 5.34 %: that much free cash flow Genmab A/S produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genmab A/S (GNMSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genmab A/S it is $528.76 per share (as of Oct 3, 2026), against a price of $355.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Genmab A/S stock overvalued or undervalued in 2026?
As of Oct 3, 2026, GNMSF trades below its calculated fair value: price $355.00, fair value $528.76, a gap of about +49% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GNMSF?
No. The price is what the market pays today ($355.00); the fair value is what the company's own numbers justify ($528.76). For Genmab A/S the two are $173.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genmab A/S worth?
The market values Genmab A/S at about $22.3B (market capitalisation, as of Oct 3, 2026). Per share that is $355.00; our models calculate a fair value of $528.76 per share.
What do the bullish and bearish scenarios say about GNMSF?
Our models span a range for Genmab A/S: cautious scenario $247.76, base $528.76, optimistic $779.69 per share (as of Oct 3, 2026, price $355.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GNMSF?
Genmab A/S trades at a price-to-earnings ratio of 27.0 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $528.76 is built from several models across several years. Other multiples: PEG 1.6, P/B 2.6, P/S 3.9, EV/EBITDA 14.0.
What is the PEG ratio of GNMSF?
The PEG ratio of Genmab A/S is 1.65 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Genmab A/S (GNMSF)?
Balance-sheet figures for Genmab A/S (as of Oct 3, 2026): return on equity 15.0%, debt of 0.86 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is GNMSF from its 52-week high?
Genmab A/S trades at $355.00, at its 52-week high of $355.00 and 53% above the low of $232.34 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $528.76 is for.
Which stocks are comparable to Genmab A/S?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genmab A/S stock attractive at the current price?
The data as of Oct 3, 2026: price $355.00, calculated fair value $528.76 (+49%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GNMSF calculated?
We run Genmab A/S through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $528.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Genmab A/S currently trades 33 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genmab A/S (GNMSF)?
The closing price on Oct 2, 2026 was $355.00. Our model-based fair value is $528.76, about +49% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genmab A/S right now?
The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($247.76 to $779.69). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Genmab A/S (GNMSF) come from?
Earnings per share at Genmab A/S grew +20.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +29.5 %, EBIT margin −5.5 %, tax rate −2.5 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Genmab A/S
How large is the market capitalisation of Genmab A/S (GNMSF)?
The market capitalisation of Genmab A/S is $22.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genmab A/S (GNMSF)?
The price-to-sales ratio of Genmab A/S is 6.99 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genmab A/S (GNMSF)?
Earnings per share at Genmab A/S are $13.15 (price ÷ EPS = P/E 27.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genmab A/S (GNMSF)?
The dividend yield of Genmab A/S is 1.8% (payout 49.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genmab A/S (GNMSF)?
The net margin of Genmab A/S is 25.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genmab A/S (GNMSF)?
The return on equity (ROE) of Genmab A/S is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genmab A/S (GNMSF)?
On an EBIT basis the return on assets of Genmab A/S is 14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genmab A/S (GNMSF)?
The operating margin of Genmab A/S is 25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genmab A/S (GNMSF)?
Revenue at Genmab A/S is growing +25.3% versus a year earlier (3y avg −35.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genmab A/S (GNMSF)?
Earnings per share at Genmab A/S are growing −72.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genmab A/S (GNMSF) carry?
The net debt of Genmab A/S is $3.8B (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genmab A/S in the live analysis
One click puts Genmab A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.